cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.18497652
title: Highway Emergency Lane Obstacle Detection & V2I Dataset

description: This dataset collects data from an autonomous vehicle in a highway scenario, focusing on the detection of stationary vehicles in the emergency lane and the subsequent Vehicle-to-Infrastructure (V2I) communication.

AUTOMATED VEHICLE DATA COLLECTOR

The vehicle used for data collection is an autonomous car prototype retrofitted with the following sensor suite:





Inertial Navigation System: OxTS GNSS/INS solution providing global position, IMU data, and odometry.




LiDAR: 1x Ouster 360° LiDAR.




Cameras: 4x Lucid Vision cameras (Front Center, Front Left, Front Right, and Rear recorded).




Radars: 4x Continental ARS430 radars providing objects list, near and far range detections.




Vehicle Sensors: Wheel speed sensors and internal vehicle feedback.



and controllable actuators:





Steering & Braking: Wire-controlled actuators for lateral and longitudinal control.



The system is designed to detect the position, velocity, and type of other road users. For this specific task, the perception stack utilizes neural networks for image segmentation to build a local map of the lanes. An algorithm processes this data to identify vehicles specifically stopped in the emergency lane.

DATASET CONTENT

The dataset includes a ~22-second recording in a real highway environment. It contains:





ROS2 Bag (.mcap): Contains all raw sensor data, system status, perception outputs and the message that will be sent to the Infrastructure.




Visualization Video: Shows the algorithm output on BEV (bounding boxes of detected vehicles; red highlighting for the vehicle detected outside the carriageway) + raw cameras. To replicate the video you need to run the ros2 bag and launch tviz2. On rviz2 open the provided config 'lane_keeping.rviz'. 



Key ROS2 Topics included (relevant list):





Sensors (Raw Data):





/ouster_sensor_center/points (LiDAR Pointcloud)




/lucid_vision/*/image_rect/compressed (Camera images)




/ces_ars430di/sensor_*/objects_list (Radar object list detections)




/oxts/nav_sat_fix & /oxts/imu (GNSS and Inertial data)






State Estimation & Localization:





/estimation/ekf/vehicle_state (Fused vehicle state)






Perception & Scene Understanding:





/perception/target_tracking/obstacles_list (Tracked object list)




/estimation/multilane_prediction/bev_image/compressed (Bird's Eye View representation of lanes)




/perception/positioning_algorithm/denm_stationary_vehicles (V2I Alert Message)





SCENARIOS





Highway: The ego-vehicle travels on the highway while a target vehicle is stationary in the emergency lane. The system detects the stationary vehicle, classifies its position relative to the lanes, and triggers a V2I warning message.



Location: A50 Tangenziale Ovest di Milano (Rozzano/Assago area), Italy.

DATASET ACCESS

To request access to the dataset please contact:

Giulio Panzani, Politecnico di Milano, giulio.panzani@polimi.it Riccardo Pieroni, Politecnico di Milano, riccardo.pieroni@polimi.it
DOI: 10.60645/bdc-k4b0-827g
title: NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (MESA)

description: 
The NHLBI "Grand Opportunity" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the "exome") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.

HeartGO is a consortium of six well-phenotyped NHLBI cohorts: Atherosclerosis Risk in Communities (ARIC) study, the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), the Jackson Heart Study (JHS), and the Multi-Ethnic Study of Atherosclerosis (MESA). Together, for the GO-ESP, these cohorts have provided DNA and phenotype datasets from a diverse cohort of individuals of African and Caucasian ancestry to be made available for use by qualified investigators in dbGaP. HeartGO investigators will conduct genotype-phenotype analyses for phenotypes related not only to heart disease but with other variables that will be contributed to dbGaP. The HeartGO dataset provides investigators with genotype-phenotype analytic opportunities for traits not only related to heart disease but also associated with ancillary variables that will be contributed to dbGaP, including disease endpoints, risk factors, biomarkers, and subclinical disease measures.

The phenotypes planned for investigation as part of the GO-ESP HeartGO project include five primary phenotypes for which initial ascertainment of samples for exome sequencing were made (early-onset myocardial infarction (EOMI), low density lipoprotein (LDL) cholesterol, body mass index/type 2 diabetes (BMI/T2D), blood pressure and ischemic stroke) and a randomly ascertained common comparison group with extensive phenotyping (deeply phenotyped reference, DPR). Additional phenotypes available on these selected samples permitted a large array of additional analyses to be performed. These secondary phenotypes account for ~80 outcomes from both qualitative and quantitative traits. Results of the proposed analyses as well as relevant replication/follow-up analyses will be reported in peer-reviewed journals.
DOI: 10.60645/bdc-78b3-nc6h
title: NHLBI GO-ESP: Heart Cohorts Exome Sequencing Project (MESA)

description: 
The NHLBI "Grand Opportunity" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the "exome") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.

HeartGO is a consortium of six well-phenotyped NHLBI cohorts: Atherosclerosis Risk in Communities (ARIC) study, the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), the Jackson Heart Study (JHS), and the Multi-Ethnic Study of Atherosclerosis (MESA). Together, for the GO-ESP, these cohorts have provided DNA and phenotype datasets from a diverse cohort of individuals of African and Caucasian ancestry to be made available for use by qualified investigators in dbGaP. HeartGO investigators will conduct genotype-phenotype analyses for phenotypes related not only to heart disease but with other variables that will be contributed to dbGaP. The HeartGO dataset provides investigators with genotype-phenotype analytic opportunities for traits not only related to heart disease but also associated with ancillary variables that will be contributed to dbGaP, including disease endpoints, risk factors, biomarkers, and subclinical disease measures.

The phenotypes planned for investigation as part of the GO-ESP HeartGO project include five primary phenotypes for which initial ascertainment of samples for exome sequencing were made (early-onset myocardial infarction (EOMI), low density lipoprotein (LDL) cholesterol, body mass index/type 2 diabetes (BMI/T2D), blood pressure and ischemic stroke) and a randomly ascertained common comparison group with extensive phenotyping (deeply phenotyped reference, DPR). Additional phenotypes available on these selected samples permitted a large array of additional analyses to be performed. These secondary phenotypes account for ~80 outcomes from both qualitative and quantitative traits. Results of the proposed analyses as well as relevant replication/follow-up analyses will be reported in peer-reviewed journals.
DOI: 10.60645/bdc-1657-7fuv
title: NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Asthma)

description: 
The NHLBI "Grand Opportunity" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the "exome") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO.

The exome sequencing asthma project includes 200 African-Americans with asthma from the NHLBI multicenter Severe Asthma Research Program (SARP). SARP participants were recruited at the NHLBI SARP sites with an emphasis on recruiting severe asthmatics (Moore et al., Am J Respir Crit Care Med, 2010. PMID: [19892860](http://www.ncbi.nlm.nih.gov/pubmed/19892860)). Asthma status was based on both a physician&#39;s diagnosis and either bronchodilator reversibility or hyper-responsiveness to methacholine as well as less than 5 pack years of smoking. All subjects were carefully characterized using the standardized SARP protocol which included spirometry (medication withheld), maximum bronchodilator reversibility, hyper-responsiveness to methacholine (not performed in subjects with low baseline FEV1), skin-tests to common allergens, questionnaires on health care utilization and medication use and sputum, lung imaging and bronchoscopy in a subset. In addition GWAS data are available ([phs000355](./study.cgi?study_id=phs000355), Illumina platform).
DOI: 10.60645/bdc-5i85-7asi
title: PGRN-RIKEN: Identification of Genetic Predictors of ACE Inhibitor-Associated Angioedema

description: 
The purpose of this study is to identify genetic predictors of ACE inhibitor-associated angioedema. In addition to preventing the formation of the pressor angiotensin II, ACE inhibitors prevent the carboxyl-terminal degradation of the vasoactive substances bradykinin and substance P. Angioedema is hypothesized to result from defective amino-terminal degradation of bradykinin or substance P in patients in whom ACE is inhibited. For example, activity of dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for the inactivation of substance P when ACE is inhibited, is decreased in patients with angioedema. In preliminary studies, we have identified SNPs in the DPP4 gene that associate with DPP-IV activity and, in blacks, with risk of angioedema.

This project will use genome-wide genotyping to compare 250 cases and 568 ACE inhibitor-exposed control subjects (131 cases and 288 controls ascertained at Vanderbilt and 70 cases and 280 controls ascertained at the Marshfield Clinic). We plan a 2-stage analysis of associations between SNPs and angioedema - first, we will study DPP4 SNPs for association with angioedema and, second, we will explore associations using the full GWAS data set. Depending on the platform, additional DPP4 SNPs will be used to fully tag common genetic variants in both African American and European American samples. Based on the HapMap data, there are 14 tagging SNPs in people of European descent and 34 in Yoruba (selection criteria MAF&gt;0.05 and r2&gt;0.8).

Cases were defined as having ACE inhibitor-associated angioedema if they had had swelling of the lips, throat, tongue or face while taking an ACE inhibitor but had never had angioedema while not taking an ACE inhibitor. For simplicity, intestinal edema was excluded. Control subjects were treated for at least 6 months with an ACE inhibitor without angioedema. Because black Americans are known to be overrepresented among patients with ACE inhibitor-associated angioedema, control subjects were prespecified to be 50% black American, 50% white American, and 50% female. At Vanderbilt, the medical history, including the history of angioedema, was confirmed by a research nurse or physician using a detailed case report form. Characteristics of Vanderbilt cases appear in the Table. At Marshfield, medical history will be confirmed by chart review. The Marshfield cohort is 98% white American and 57% female with a mean age of 47.2 years.
DOI: 10.60645/bdc-7w62-lr88
title: PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation

description: 
The goal of this study was to identify genetic predictors of response to rate control therapy in patients with AF. We conducted a genome-wide association study (GWAS) focusing on subjects with a history of atrial fibrillation. Rate control therapy for AF uses a range of drugs (beta-adrenergic receptor blockers, calcium channel blockers, and digitalis) to depress conduction through the AV node, thereby preventing rapid rates and minimizing symptoms. In large groups of patients, such as the Vanderbilt AF Registry (a clinical and genetic repository with over 1200 patients with ECG-confirmed AF) from which these study subjects were drawn, approximately 5% display failure of aggressive AV nodal-blocking therapy to control ventricular rate. In these patients, interruption of the AV node by ablation and pacemaker implantation are necessary for adequate rate control.

Study cases were individuals who underwent AV node ablation and pacemaker implantation after combined therapy with 3 AV nodal-blocking agents was ineffective in rate control. Controls for this study were individuals who met standardized rate-control efficacy criteria (as described in AFFIRM study, Wyse et al, NEJM 2002; PMID: [12466506](http://www.ncbi.nlm.nih.gov/pubmed/12466506)) for optimal rate control with 2 or fewer AV nodal-blocking agents. Two additional groups were genotyped by RIKEN: An additional group of patients with AF as well as subjects undergoing cardiac surgery in whom AF did not occur post-operatively. All study participants were recruited and treated/evaluated at Vanderbilt University Medical Center.

This study was conducted by the Pharmacogenomics of Arrhythmia Therapy subgroup of the Pharmacogenetics Research Network, a nationwide collaboration of scientists studying the genetic contributions to drug response variability. Genotyping was performed by the RIKEN research institute in Japan using the Illumina 610 Quad Beadchip platform.
DOI: 10.60645/bdc-86f4-og1q
title: Drug Resistant Hypertension in African Americans&#39; Exome

description: 
Resistant hypertension is defined as blood pressure that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes or the concurrent use of 4 or more antihypertensive agents regardless of control. Its diagnosis is important for the identification of patients who are at high risk of having reversible causes of hypertension and/or patients who, because of persistently high blood pressure levels, may benefit from special diagnostic and therapeutic considerations. Resistant hypertension represents an extreme phenotype, thus, it has been predicted that genetic factors could play a larger role than for the general hypertensive population. Genetic assessments of patients with resistant hypertension have been limited. The current study assayed the exome of 91 African American patients with treatment resistant hypertension.
DOI: 10.60645/bdc-z5jr-bo94
title: NHLBI Exome Sequencing in SCID

description: 
Analysis of the molecular etiologies of severe combined immunodeficiency (SCID) has led to important insights into the control of immune cell development. Most cases of SCID result from either X-linked or autosomal recessive inheritance of mutations in a known causative gene. However, in some cases, the molecular etiology remains unclear. To identify the cause of SCID in a patient known to lack the protein tyrosine phosphatase CD45, we utilized single nucleotide polymorphisms (SNP) arrays and whole exome sequencing. The patient&#39;s mother was heterozygous for an inactivating mutation in *CD45*, while the paternal alleles lacked mutations. The patient exhibited a single *CD45* mutation identical to the maternal allele. Patient SNP array analysis revealed no change in copy number but loss of heterozygosity for the entire length of chromosome 1 (Chr1), indicating that disease was caused by uniparental disomy (UPD) with isodisomy of the entire maternal Chr1 bearing the *CD45* mutation. Non-lymphoid blood cells and other mesoderm and ectoderm-derived tissues retained UPD of the entire maternal Chr1 in this patient who had undergone successful bone marrow transplantation. Exome sequencing revealed mutations in 7 additional genes bearing nonsynonymous SNPs predicted to have deleterious effects. These findings represent the first reported case of SCID caused by UPD and suggest UPD should be considered in SCID and other recessive disorders, especially when the patient appears homozygous for an abnormal gene found in only one parent. Evaluation for alterations in other genes affected by UPD should also be considered in such cases.
DOI: 10.60645/bdc-81d0-026y
title: Cholesterol and Pharmacogenetics (CAP) Study

description: 
The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 black and 609 white (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations with baseline measurements and changes in response to simvastatin treatment. 

Whole genome genotyping was performed on 592 white CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 participants were genotyped, including 280 who were genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies. More recently, CAP self-reported black participants were genotyped on Illumina Omni2.5Exome chips.

PolyA-selected strand-specific RNA-seq libraries were generated in several batches from lymphoblastoid cell lines (LCLs) derived from 268 white and 165 black CAP participants. The LCLs were exposed to sham buffer (control) or 2 uM activated simvastatin for 24 hours, producing a total of 866 100/101 bp paired end RNA-seq libraries sequenced on Illumina HiSeq 2000 machines.
DOI: 10.18150/ib0wjp
title: Dataset on the effect of drive level on measurement results of QCM sensor characteristics

description: This dataset comprises measurements of the impedance characteristics of a quartz microbalance and the corresponding variations in sensor temperature under different excitation signal conditions.The set of data contains:Data_description.txt - additional, more detailed information about the conditions of the experimentB3_Holder_a.png – schematic cross-sectional diagram of the holder developed for the purposes of the experimentB3_Holder_b.png – photograph of the sensor mounted in a holderB3_Z_DL1.txt – measurement data of sensor impedance characteristics under DL1 excitation conditionsB3_Z_DL2.txt – measurement data of sensor impedance characteristics under DL2 excitation conditionsB3_T_DL2.txt – measurement data of sensor temperature changes under DL2 excitation conditionsB3_Z_DL3.txt – measurement data of sensor impedance characteristics under DL3 excitation conditionsB3_T_DL3.txt – measurement data of sensor temperature changes under DL3 excitation conditionsPlease read the ReadMe.txt and Data_description.txt file for additional information.The dataset was prepared as part of the National Science Centre Miniatura 8 research grant, DEC-2024/08/X/ST7/01125, entitled: Badanie wpływu niehomogenicznych pól termicznych na charakterystykę odpowiedzi wysokoczułych sensorów piezoelektrycznych. (Analysis of the influence of non-homogeneous thermal fields on the response characteristics of highly sensitive piezoelectric sensors). The project was carried out by dr. Sylwester Nowocień at the Wrocław University of Science and Technology, Faculty of Electronics, Photonics and Microsystems.
DOI: 10.60645/bdc-j5ay-1e61
title: Women&#39;s Health Initiative Sight Examination (WHISE)

description: 
This substudy phs000503 WHISE contains phenotypes only for the Sight Examination study. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](./study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](./study.cgi?study_id=phs000200). 

Women enrolled in the Women&#39;s Health Initiative (WHI) Hormone Replacement Therapy (HRT) Clinical Trial (CT) were included in this study. In WHI, participants who did not have a hysterectomy before enrollment into the WHI HRT CT were randomly assigned to either conjugated equine estrogens with progestin (CEE P) (0.625 mg/d of CEE and 2.5 mg/d of progestin) or a placebo. Those without a uterus were randomly assigned to either CEE (0.625 mg/d) or a placebo. Participants in the WHISE Study were recruited an average of 5.1 years after randomization into the WHI HRT CT. Participants included 4688 women who consented to participate in the WHISE Study; 4347 completed enrollment with photographs of at least 1 eye. The purpose of the study was to evaluate the effects of HRT on age-related macular degeneration.
DOI: 10.60645/bdc-73s5-bxi2
title: Women&#39;s Health Initiative Sight Examination (WHISE)

description: 
This substudy phs000503 WHISE contains phenotypes only for the Sight Examination study. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](./study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](./study.cgi?study_id=phs000200). 

Women enrolled in the Women&#39;s Health Initiative (WHI) Hormone Replacement Therapy (HRT) Clinical Trial (CT) were included in this study. In WHI, participants who did not have a hysterectomy before enrollment into the WHI HRT CT were randomly assigned to either conjugated equine estrogens with progestin (CEE P) (0.625 mg/d of CEE and 2.5 mg/d of progestin) or a placebo. Those without a uterus were randomly assigned to either CEE (0.625 mg/d) or a placebo. Participants in the WHISE Study were recruited an average of 5.1 years after randomization into the WHI HRT CT. Participants included 4688 women who consented to participate in the WHISE Study; 4347 completed enrollment with photographs of at least 1 eye. The purpose of the study was to evaluate the effects of HRT on age-related macular degeneration.